Protocol Ledger

NCT04884282 · Phase II · ACTIVE NOT RECRUITING

Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

Interventional Phase II clinical trial protocol NCT04884282 sponsored by Fondazione Ricerca Traslazionale in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-10-12 Enrollment: 105 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04884282
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)105 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04884282
Protocol FieldVerified Registry Value
NCT IdentifierNCT04884282
Consolidated Lead SponsorFondazione Ricerca Traslazionale
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment105 participants (ESTIMATED)
Registered Start Date2021-10-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04884282
Hospital Research SiteLocationSite Profile
Institut Sainte CatherineAvignon, FranceOpen Hospital Dossier ->
Azienda Ospedaliero Universitaria CareggiFlorence, ItalyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI